GSK, partner Theravance target December for heart disease drug decision
GSK
Research Triangle Park, N.C. —
The acceptance of the NDA indicates that the application is sufficiently complete to permit a substantive review, and a target date of December was set for possible market approval.
In December 2012 and January 2013, GSK and Theravance said regulatory applocations had been made in both the U.S. and Europe.
UMEC/VI, with proposed brand name ANORO, is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist (LABA), administered using the ELLIPT inhaler.
GSK operates its North American headquarters in RTP.
[GSK ARCHIVE: Check out more than a decade of GSK stories as reported in WRAL Tech Wire.]
...
WRAL Tech Wire any time: Twitter, Facebook
Copyright 2013 WRAL Tech Wire. All rights reserved.Please log in to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
The Skinny
NC Biotech Center braces for worst as Senate slashes budget, too- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows